Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Obesity

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 62 articles: HTML format

Single Articles

May 2025
1. ARONNE LJ, Horn DB, le Roux CW, Ho W, et al
   Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
   N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394.
   PubMed     Abstract available
   
   
   
2. FOX CK, Harder-Lauridsen NM, Arslanian S
   Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.
   N Engl J Med. 2025;392:1868.
   PubMed    
   
   
   
3. EGAN JM, Kapogiannis D
   Liraglutide for Children 6 to <12 Years of Age with Obesity.
   N Engl J Med. 2025;392:1866-1868.
   PubMed    
   
   
   
4. JI C, Wang M
   Liraglutide for Children 6 to <12 Years of Age with Obesity.
   N Engl J Med. 2025;392:1867.
   PubMed    
   
   
   
5. MALOZOWSKI S
   Liraglutide for Children 6 to <12 Years of Age with Obesity.
   N Engl J Med. 2025;392:1866-1867.
   PubMed    
   
   
   April 2025
6. PACKER M, Kramer CM, Borlaug BA
   Tirzepatide for Heart Failure and Obesity. Reply.
   N Engl J Med. 2025;392:1661-1662.
   PubMed    
   
   
   
7. ALI MK
   Tirzepatide for Heart Failure and Obesity.
   N Engl J Med. 2025;392:1661.
   PubMed    
   
   
   
8. MARINE JE, Mandrola J, Prasad V
   Tirzepatide for Heart Failure and Obesity.
   N Engl J Med. 2025;392:1660.
   PubMed    
   
   
   
9. KRAKAUER JC, Krakauer NY
   Tirzepatide for Heart Failure and Obesity.
   N Engl J Med. 2025;392:1660.
   PubMed    
   
   
   
10. WAGNER J
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1659-1660.
    PubMed    
    
    
    November 2024
11. PACKER M, Zile MR, Kramer CM, Baum SJ, et al
    Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027.
    PubMed     Abstract available
    
    
    
12. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414470.
    PubMed    
    
    
    
13. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    October 2024
14. BLIDDAL H, Bays H, Czernichow S, Udden Hemmingsson J, et al
    Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
    N Engl J Med. 2024;391:1573-1583.
    PubMed     Abstract available
    
    
    
15. 
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024;391:1464.
    PubMed    
    
    
    September 2024
16. DRUCKER DJ
    Discovery of GLP-1-Based Drugs for the Treatment of Obesity.
    N Engl J Med. 2024 Sep 19. doi: 10.1056/NEJMcibr2409089.
    PubMed    
    
    
    
17. BARRETT T, Hamilton-Shield J
    Childhood Obesity and GLP-1 Receptor Agonists - A Coming of Age?
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMe2410560.
    PubMed    
    
    
    
18. FOX CK, Barrientos-Perez M, Bomberg EM, Dcruz J, et al
    Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2407379.
    PubMed     Abstract available
    
    
    July 2024
19. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
20. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
21. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
22. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    June 2024
23. MALHOTRA A, Grunstein RR, Fietze I, Weaver TE, et al
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024 Jun 21. doi: 10.1056/NEJMoa2404881.
    PubMed     Abstract available
    
    
    
24. 
    Treating Obesity in Kids: ITT Episode 31.
    N Engl J Med. 2024;390:e52.
    PubMed    
    
    
    May 2024
25. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
26. EGAN JM
    Physiological Integration of Taste and Metabolism.
    N Engl J Med. 2024;390:1699-1710.
    PubMed    
    
    
    April 2024
27. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    February 2024
28. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    
    
    
    
29. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    
    
    
    
30. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
31. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
32. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    
    
    
    
33. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    
    
    
    
34. GORTMAKER SL, Bleich SN, Williams DR
    Childhood Obesity Prevention - Focusing on Population-Level Interventions and Equity.
    N Engl J Med. 2024;390:681-683.
    PubMed    
    
    
    
35. GOLOVATY I, Hagan S
    Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
    N Engl J Med. 2024;390:677-680.
    PubMed    
    
    
    December 2023
36. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    
    
    
    
37. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
38. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
39. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    
    
    
    
40. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    
    
    
    
41. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    
    
    
    
42. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    
    
    
    November 2023
43. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    
44. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    
    
    
    October 2023
45. JASTREBOFF AM, Kaplan LM, Hartman ML
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
    N Engl J Med. 2023;389:1629-1630.
    PubMed    
    
    
    
46. ELFEKI MA, Alkhouri N
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1629.
    PubMed    
    
    
    
47. BISSON A, Fauchier G, Fauchier L
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1628.
    PubMed    
    
    
    
48. HANNON TS, Arslanian SA
    Obesity in Adolescents. Reply.
    N Engl J Med. 2023;389:1344.
    PubMed    
    
    
    
49. BHOWMIK S, Mahapatra HS
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343-1344.
    PubMed    
    
    
    
50. ABU DAYYEH B, Stier C
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343.
    PubMed    
    
    
    August 2023
51. 
    Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    
    
    
    
52. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available
    
    
    
53. PATTI ME
    Triple G Agonists - A Home Run for Obesity?
    N Engl J Med. 2023;389:562-563.
    PubMed    
    
    
    July 2023
54. HANNON TS, Arslanian SA
    Obesity in Adolescents.
    N Engl J Med. 2023;389:251-261.
    PubMed    
    
    
    June 2023
55. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available
    
    
    
56. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available
    
    
    
57. STOOPS H, Dar M
    Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
    N Engl J Med. 2023;388:2309-2311.
    PubMed    
    
    
    
58. ROSEN CJ
    Antagonizing the Leptin Receptor in Obesity.
    N Engl J Med. 2023;388:2291-2293.
    PubMed    
    
    
    
59. FUNCKE JB, Moepps B, Roos J, von Schnurbein J, et al
    Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.
    N Engl J Med. 2023;388:2253-2261.
    PubMed     Abstract available
    
    
    March 2023
60. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    
    
    
    
61. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    
    
    
    
62. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge.